GSKure

Therapeutic Target for Treating Neurogenetic Disorders

Active Pre-Funding Startup Tel Aviv-Yafo Founded 2016-01

Website ↗

GSKure is an IP-based company that owns innovative proprietary GSK-3 peptide inhibitor drug candidates. The company's Kure products are based on a novel design of compounds that target a unique region at the GSK-3 protein surface termed the substrate binding site. The substrate-competitive inhibitors (SCIs) show improved selectivity and low toxicity compare…